Business
Willow Biosciences Provides Update on Cannabigerol Research Studies and Key Personnel Appointment
Willow Biosciences Provides Update on Cannabigerol Research Studies and Key Personnel App...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n Willow Biosciences Provides Update on Cannabigerol Research Studies and Key Personnel Appointment\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VANCOUVER, BC\n \n ,\n \n Jan. 13, 2021\n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it is undertaking two initiatives to help our customers evaluate and better understand cannabigerol (\"\n \n CBG\n \n \"), our first commercial cannabinoid slated for production in Q1 2021.\n \n \n \n \n \n \n \n \n \n Willow has engaged Signum Biosciences, a leading biopharmaceutical company focused on the discovery and development of innovative consumer products, to generate a robust safety and data package for our CBG to demonstrate its safety and activity as a cosmetic ingredient.  The Company has also engaged a world-renowned regulatory consulting group to perform a comprehensive safety assessment to independently conclude that our CBG is Generally Regarded As Safe (GRAS) for use as an ingredient in food and beverage products and support future novel food submissions in multiple jurisdictions.\n \n \n \"The work we are doing to study the safety and activity of CBG will help to separate us from the rest of the industry,\" said\n \n Trevor Peters\n \n , Willow's President and Chief Executive Officer. \"We expect to supply our customers with highly pure product and provide them with the tools they need to create a diverse set of consumer products with CBG.\"\n \n \n To support the above product development initiatives and further expand our knowledge of phytocannabinoids, the Company is pleased to announce the appointment of Dr.\n \n Mathias Schuetz\n \n to Vice President, Plant Science. Dr. Schuetz was previously Vice President, Research & Development.  The Company is also pleased to announce the promotion of Dr.\n \n Trish Choudhary\n \n to Vice President, Research & Development to lead our yeast strain engineering efforts. Dr. Choudhary has been with...